ReviewArthritis research & therapy2017
Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance.
Review in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.Arthritis research & therapy · 2026Trial
- Impact of Biologic and Targeted Synthetic Therapies on Retinal and Choroidal Parameters Assessed by Optical Coherence Tomography Angiography.Biomedicines · 2026Article
- Platelet Indices as Unequivocal Markers of Active Disease in Patients With Nonradiographic Axial Spondyloarthritis: Protocol for a Cross-Sectional Study.JMIR research protocols · 2025Article
- Posture, balance and gait in axial spondyloarthritis: a case-control study.Rheumatology international · 2024Article
- Characteristics and burden of disease in patients with radiographic versus non-radiographic axial spondyloarthritis in the ASRI cohort.Irish journal of medical science · 2024Article
- Clinical significance of possible HLA biomarkers in axial spondyloarthritis beyond HLA-B27 positivity.Rheumatology international · 2023Article
- Understanding the paradigm of non-radiographic axial spondyloarthritis.Clinical rheumatology · 2021Review
- The role of ixekizumab in non-radiographic axial spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2021Article
- Evaluating Inflammatory Versus Mechanical Back Pain in Individuals with Psoriatic Arthritis: A Review of the Literature.Rheumatology and therapy · 2020Review
- Content validity of the ASQoL for use in a non-radiographic axial spondyloarthritis population: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.Rheumatology and therapy · 2020Article
- Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States.Rheumatology and therapy · 2020Article
- Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.Therapeutic advances in musculoskeletal disease · 2020Review
- Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy.Rheumatology and therapy · 2019Review
- The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures.Frontiers in medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current classification criteria for axial spondyloarthritis (axSpA) provide for the inclusion of patients with a wide range of presentations and manifestations. While not considered a formal subclassification, patients are often divided into radiographic or nonradiographic axSpA based on the presence or absence of radiographic sacroiliitis. This review will focus on nonradiographic axSpA and will discuss clinical manifestations of disease that distinguish, or in many cases do not distinguish, this entity from other individuals with axSpA. This review will also cover treatment paradigms for nonradiographic axSpA, particularly the use of biologic therapies, where current data suggest that nonradiographic disease should be managed largely the same as radiographic disease, or classical ankylosing spondylitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.